Oxford-Astrazeneca vaccine doesn’t need to be stored in ultra-low temperatures which makes it easier to be distributed in low-and-middle-income countries
The results of Pfizer and Moderna have already shown the light of hope and now the results of a large-scale trial of Oxford-AstraZeneca vaccine candidates have been welcomed by the healthcare experts and the government. Professor Chris Whitty, UK’s chief medical officer tweeted that it was a « very encouraging step forward » and in the same tweet, he thanked those who volunteered and the researchers around the world. After the news came out, UK Prime Minister Boris Johnson tweeted, « Incredibly exciting news the Oxford vaccine has proved so effective in trials. There are still further safety checks ahead, but these are fantastic results. » The Oxford vaccine was revealed to be 70 percent effective against the Coronavirus, but as per researchers, it can be up to 90 percent effective when one-half dose is administrated followed by a full dose at least one month apart. The UK has placed orders for 100 million vaccine doses that will be enough to immunize most of the population if it gets approval. Matt Hancock, UK health secretary said life in the country could return to normal after Easter. The UK government has also ordered 40 million doses of the Pfizer-BioNTech vaccine which is claimed to be 95 percent effective. The country has also ordered 5 million doses of the Moderna vaccine which is 94.
